TCT-168 TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold implantation for recovery of vascular function after successful Chronic Total Occlusion recanalization

At linear mixed model, CBF exhibited significantly higher values in the Ticagrelor as compared to Clopidogrel group during multiple stepwise adenosine infusion, even after adjustment for age (p=0.029; Figure 1). Conclusion The TIGER BVS trial showed that Ticagrelor may be efficacious in improving co...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 70; no. 18; p. B72
Main Authors Brugaletta, Salvatore, Lara, Josep Gomez, Caballero-Borrego, Juan, Ortega-Paz, Luis, Gila, Luis Teruel, Jimenez, Miriam, Romaguera, Rafael, Martinez, Vicente Alcalde, Ñato, Marcos, Molina, Eduardo, Gomez-Hospital, Joan Antoni, Vilchez, Concepcion Correa, Cequier, Angel, Sabate, Manel
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 31.10.2017
Elsevier Limited
Subjects
Biocompatibility
Biomedical materials
Cardiology
Implantation
Occlusion
Recovery (Medical)
Surgical implants
Online AccessGet full text

Cover

More Information
Summary:At linear mixed model, CBF exhibited significantly higher values in the Ticagrelor as compared to Clopidogrel group during multiple stepwise adenosine infusion, even after adjustment for age (p=0.029; Figure 1). Conclusion The TIGER BVS trial showed that Ticagrelor may be efficacious in improving coronary vascular flow in CTO patients as compared to Clopidogrel.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.235